HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) web only appendices All Versions of this Article: jmg.2007.051318v1 44/12/787    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Heyningen, V. v. Articles by Crolla, J. A Search for Related Content PubMed PubMed Citation Articles by Heyningen, V. v. Articles by Crolla, J. A

Raised risk of Wilms tumour in patients with aniridia and submicroscopic WT1 deletion

¹ MRC Human Genetics Unit, Western General Hospital, Edinburgh, UK
² Department of Clinical Genetics, Academic Medical Centre, Amsterdam, The Netherlands
³ Department of Pediatric Oncology, Emma Children’s Hospital, Academic Medical Centre, Amsterdam, The Netherlands
⁴ Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, UK

Correspondence to:
Veronica van Heyningen, MRC Human Genetics Unit, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; v.vanheyningen{at}hgu.mrc.ac.uk]

ABSTRACT
Objective: The aim of this study was to determine if there is a significant difference in the risk of developing Wilms tumour between patients with submicroscopic and those with visible deletions of the WT1 tumour suppressor gene.

Methods: To determine which subjects had WT1 deletions, high-resolution chromosomal deletion analysis of the 11p13 region was carried out in 193 people with aniridia. The rationale for this was that aniridia is caused by loss of function of one copy of the PAX6 gene, and although most patients with aniridia have intragenic mutations, a proportion has deletions that also include the nearby WT1 gene. Fluorescence in situ hybridisation (FISH) analysis of patients with aniridia identifies people with WT1 deletions regardless of whether they have Wilms tumour, allowing the deletion size to be correlated with clinical outcome.

Results: Wilms tumour was not observed in any case without a WT1 deletion. Of subjects in whom WT1 was deleted, 77% with submicroscopic deletions (detectable only by high-resolution FISH analysis) presented with Wilms tumour compared with 42.5% with visible deletions (detectable by microscopy). This difference was significant.

Conclusions: High-resolution deletion analysis is a useful tool for assessing the risk of Wilms tumour in neonates with aniridia. People with submicroscopic WT1 deletions have a significantly increased risk of Wilms tumour, and a high level of vigilance should be maintained in such cases.

Abbreviations: ESRD, end-stage renal disease; FISH, fluorescence in situ hybridisation; OMIM, Online Mendelian Inheritance in Man; WAGR, Wilms tumour, aniridia, genitourinary anomalies and mental retardation; WT, Wilms tumour

Keywords: aniridia; Wilms tumour; WAGR; deletion; FISH